Opthea Ltd Stock Price, News & Analysis

Welcome to our dedicated page for Opthea news (Ticker: OPT), a resource for investors and traders seeking the latest updates and insights on Opthea stock.

Opthea Limited (ASX: OPT) generates frequent news as a clinical-stage biopharmaceutical company developing therapies for retinal diseases such as wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Company announcements describe the progress of its lead product candidate, sozinibercept, a first-in-class VEGF-C/D ‘trap’ inhibitor studied in combination with standard-of-care anti-VEGF-A therapies.

News items for OPT commonly cover clinical milestones, including Phase 2b and Phase 3 trial updates in wet AMD, early-stage data in DME, and presentations of trial results and subgroup analyses at scientific meetings and in peer-reviewed journals. Opthea also releases updates on manufacturing activities, such as completion of drug substance and drug product Process Performance Qualification campaigns to support potential regulatory filings.

Investors following OPT news will also see corporate and capital markets developments. These include half-year financial reports, cash runway commentary, capital raising outcomes, and details of a Development Funding Agreement and its subsequent settlement. The company has reported that primary endpoints were not met in its COAST and ShORe Phase 3 wet AMD trials and has described the decision, together with its DFA investors, to discontinue development of sozinibercept in wet AMD, along with workforce reductions, management changes, and a planned strategic review.

Regulatory and listing updates also appear in Opthea’s news flow, such as announcements related to its intention to voluntarily delist American Depositary Shares from The Nasdaq Global Select Market. For readers interested in the intersection of ophthalmology, clinical trial data, and biotech corporate strategy, the OPT news feed provides ongoing context on Opthea’s programs and corporate actions.